Lesson of the month: Severe granulomatosis with polyangiitis (GPA): a diagnostic challenge during the COVID-19 pandemic

Authors: Qurratulain Qurratulain, A Azeem Ahmed and Quentin Jones

We present the case of a 71-year-old woman with bilateral pneumonia who continued to deteriorate despite multiple courses of antibiotics. When dexamethasone was added to cover the possibility of COVID-19 pneumonia, she rapidly improved. Subsequently, she was found to have a strongly positive PR3 anti-nuclear cytoplasmic antibody (ANCA) and clinical features consistent with granulomatosis with polyangiitis (GPA) with upper respiratory tract and renal involvement. The case highlights how the COVID-19 pandemic can create new challenges in the diagnosis of GPA.

KEYWORDS: COVID-19, atypical pneumonia, granulomatosis with polyangiitis (GPA), anti-nuclear cytoplasmic antibodies (ANCA)

DOI: 10.7861/clinmed.2020-0793

Case presentation

A 71-year-old woman with no past medical history presented to our acute medical unit with a 1-week history of non-productive cough, fever and shortness of breath. A chest X-ray (CXR; Fig 1) showed left mid-zone consolidation. Blood results revealed a markedly elevated C-reactive protein (CRP) of 260 mg/L. Routine bloods including urea, creatinine and liver function tests were all normal. COVID-19 nasopharyngeal swabs were negative. Her CURB-65 score was 1. She was discharged home on oral antibiotics for 5 days with advice to self-isolate.

She re-presented 2 weeks later to the acute medical unit with fever, malaise, shortness of breath and cough with occasional mild haemoptysis. She had received two further courses of antibiotics in the community during the previous 2 weeks. Her oxygen saturations were 88% on air.

A repeat CXR revealed a worsening left-sided consolidation and new right upper lobe consolidation. Her CRP was 323 mg/L. A computed tomography (CT) of the chest (Fig 2) showed bilateral predominantly upper zone consolidation and small pleural effusions. She was treated with intravenous antibiotics for presumed severe pneumonia.

None of the initial tests to find the cause of the pneumonia were helpful. Her COVID-19 test was again negative. Blood, pleural fluid and sputum cultures were negative. Legionella and pneumococcal urinary antigen tests were negative, as were markers of fungal infection including aspergillus serology and B-D glucan. She also had a negative HIV test.

It was felt that COVID-19 pneumonia was still within the differential diagnosis despite negative testing. The patient was started on 6 mg of dexamethasone daily orally as in the RECOVERY trial which had recently demonstrated benefit in hypoxic patients with COVID-19 pneumonia.

After 24 hours, there was a marked clinical improvement and her inflammatory markers started to fall. She had a vasculitis screen sent earlier and the result now became available. Her anti-nuclear cytoplasmic antibodies (ANCA) test was positive with strongly positive PR3 antibody at 117 IU/mL (range 0–3.1).

A rheumatology review noted symptoms of rhinorrhoea, nasal crusting and epistaxis for the past few months, consistent with a diagnosis of granulomatosis with polyangiitis (GPA). A protein–creatinine ratio of 100 mg/mmol suggested renal involvement.

The patient was treated with oral prednisolone 1 mg/kg and started on rituximab infusion during her admission. Three days after receiving rituximab she was well enough to be discharged home.

Discussion

Clinical features of GPA

GPA is a life-threatening multisystem disease characterised by granulomatous inflammation, tissue necrosis and vasculitis in small and medium vessels. It can affect virtually any organ, but
Diagnosis of GPA during the COVID-19 pandemic

The COVID-19 pandemic presents an added difficulty in making the diagnosis of GPA. The problem is that the clinical and radiological features can be quite similar and some commonly used diagnostic tests for COVID-19 have low sensitivity (nasal swabs about 63% and pharyngeal swabs 32%). An observational study of patients with mild or moderate COVID-19 found symptoms similar to those seen in GPA, including loss of smell (70.2%), nasal obstruction (67.8%), cough (63.2%), asthma (63.3%), myalgia (62.5%), rhinorrhea (60.1%), gustatory dysfunction (56.2%), sore throat (52.9%) and fever (45.4%). Haemoptysis is not always present in GPA and may occur in COVID-19 pneumonia. The clinical course of COVID-19 pneumonia and GPA can be similar with deterioration and protracted course. The case presented shows that patients with unrecognised GPA treated as COVID-19 pneumonia can improve after steroid administration, providing false reassurance and masking the real diagnosis.

Conclusion

This case highlights how a diagnosis of GPA should be considered in patients with atypical/non-resolving pneumonia, and how steroid treatment to cover the possibility of COVID-19 pneumonia can mask GPA. Revisiting the history and requesting further investigations, including ANCA, can be key in making the right diagnosis.

References